• News
  • Technology

CardioCell gets IND approval from FDA

San Diego-based CardioCell LLC on Wednesday received the Food and Drug Administration’s investigational new drug (IND) approval for a phase 2a clinical study using its allogeneic stem-cell therapy to treat subjects with chronic heart failure (CHF).

To continue reading, subscribe now
log in to your account
User Response
0 UserComments
Subscribe Today!